Guangdong Hengrui Pharmaceutical Co., Ltd Drug Pipeline

Guangdong Hengrui Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 47 trials registered since 2008, including 31 currently active. The pipeline spans early- to late-stage development, with a breakdown of 9 active Phase 1 trials, 18 in Phase 2, and 7 in Phase 3. Clinical activity is focused across four therapeutic areas, with a notable concentration in immunology, which accounts for 42% of active programs. Within immunology, the leading indications are atopic dermatitis (6 active trials, including 2 in Phase 3), rheumatoid arthritis (3 active trials), lupus (2 active trials), psoriasis (1 active trial), and ulcerative colitis (1 active trial). Respiratory indications represent the second-largest area of activity with 9 active trials, while oncology and rare diseases each have 1 active trial. The weighting toward Phase 2 trials suggests continued expansion of the mid-stage pipeline.